Are you Dr. Zane?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1701 Divisadero St., 3rd Floor
San Francisco, CA 94143Phone+1 415-353-7800Fax+1 415-353-7870
Summary
- Dr. Lee Zane, MD is a board certified dermatologist in San Francisco, California. He is currently licensed to practice medicine in California.
Education & Training
University of California (San Francisco)Residency, Dermatology, 2000 - 2003
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1999 - 2000
Stanford University School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2000 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis Start of enrollment: 2008 Sep 01
- Cumulative Irritation Test Start of enrollment: 2008 Oct 01
- Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections Start of enrollment: 2009 Nov 05
- Join now to see all
Publications & Presentations
PubMed
- 15 citationsCrisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesEric L. Simpson, Amy S. Paller, Mark Boguniewicz, Lawrence F. Eichenfield, Steven R. Feldman
Dermatology and Therapy. 2018-10-22 - 12 citationsDeveloping drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industryElaine C. Siegfried, Jennifer C. Jaworski, Lawrence F. Eichenfield, Amy S. Paller, Adelaide A. Hebert
Pediatric Dermatology. 2018-05-01 - 37 citationsEarly relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitorGil Yosipovitch, Linda Stein Gold, Mark Lebwohl, Jonathan I. Silverberg, Anna M. Tallman
Acta Dermato-Venereologica. 2018-04-27
Press Mentions
Anacor Pharmaceuticals Announces Top-Line Results from Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients with Mild-to-Moderate Atopic DermatitisFebruary 23rd, 2016
Study Lets Teens Sound off on Acne TherapiesAugust 18th, 2008
Professional Memberships
- Fellow
